Thomson Medical narrows loss to $9.1m in H1 FY2026 on lower costs, steady performance
Loss per share stood at negative 0.039 cents; EBITDA at $38.9m.
Thomson Medical Group reported a net loss after tax of $9.1m for the six months (H1) ended 31 December 2025, narrowing 27.6% from $12.6m in the corresponding period a year earlier, according to a filing.
Loss attributable to owners was $10.2m compared with $12.9m previously, while basic and diluted loss per share were negative 0.039 cents versus negative 0.049 cents a year earlier.
The company attributed the narrower loss to lower net finance costs and steady operating performance.
"We are encouraged by the steady progress in the first half of FY2026. Revenue growth remains the clearest indicator of whether our strategy is working, and these results show that our operating businesses are responding well to the investments we have made over the past few years,” said Dr Melvin Heng, Group Chief Executive Officer of Thomson Medical
Group.
Revenue rose 7.0% year on year (YoY) to $213.1m, whilst net finance costs declined 16.1% to $24.2m.